MA31396B1 - Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes - Google Patents

Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes

Info

Publication number
MA31396B1
MA31396B1 MA32375A MA32375A MA31396B1 MA 31396 B1 MA31396 B1 MA 31396B1 MA 32375 A MA32375 A MA 32375A MA 32375 A MA32375 A MA 32375A MA 31396 B1 MA31396 B1 MA 31396B1
Authority
MA
Morocco
Prior art keywords
inhibitor
active compound
combination therapy
adp receptor
platelet adp
Prior art date
Application number
MA32375A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Pamela B Conley
Patrick Andre
Uma Sinha
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MA31396B1 publication Critical patent/MA31396B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA32375A 2007-05-02 2009-11-26 Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes MA31396B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US91591107P 2007-05-03 2007-05-03
US94792107P 2007-07-03 2007-07-03
US97870007P 2007-10-09 2007-10-09
PCT/US2008/062561 WO2008137787A2 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor

Publications (1)

Publication Number Publication Date
MA31396B1 true MA31396B1 (fr) 2010-05-03

Family

ID=39587017

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32375A MA31396B1 (fr) 2007-05-02 2009-11-26 Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes

Country Status (20)

Country Link
US (2) US20080279845A1 (https=)
EP (2) EP2146705B1 (https=)
JP (1) JP5439363B2 (https=)
KR (1) KR101509829B1 (https=)
CN (1) CN101686959B (https=)
AU (1) AU2008247435A1 (https=)
BR (1) BRPI0811000A2 (https=)
CA (1) CA2684722A1 (https=)
CO (1) CO6241105A2 (https=)
EA (1) EA020045B1 (https=)
EC (1) ECSP099775A (https=)
ES (1) ES2467468T3 (https=)
GT (1) GT200900283A (https=)
IL (1) IL201826A (https=)
MA (1) MA31396B1 (https=)
MX (1) MX2009011755A (https=)
NZ (2) NZ599556A (https=)
PT (1) PT2146705E (https=)
TN (1) TN2009000444A1 (https=)
WO (1) WO2008137787A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
KR101195801B1 (ko) * 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
MX2008014193A (es) * 2006-05-05 2009-03-31 Millennium Pharm Inc Inhibidores del factor xa.
ES2550057T3 (es) 2006-11-02 2015-11-04 Millennium Pharmaceuticals, Inc. Métodos para sintetizar sales farmacéuticas de un inhibidor del Factor Xa
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
EP2155195B1 (en) * 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2376065A2 (en) * 2008-11-14 2011-10-19 Portola Pharmaceuticals, Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
CA2784921A1 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
US8663661B2 (en) * 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
WO2011089168A2 (fr) * 2010-01-21 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition particuliere pour son application comme medicament
IN2012DN06587A (https=) * 2010-02-25 2015-10-23 Bristol Myers Squibb Co
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
TW201221128A (en) * 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
ES2539236T3 (es) * 2011-03-29 2015-06-29 Sanofi Sal de ácido benzoico de Otamixaban
WO2013033370A1 (en) * 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9695198B2 (en) 2012-12-19 2017-07-04 Merck Sharp & Dohme Corp. Factor IXa inhibitors
EP2934537B1 (en) * 2012-12-19 2018-04-04 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9708308B2 (en) 2012-12-19 2017-07-18 Merck Sharp Dohme Corp. Factor IXa inhibitors
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US9676723B2 (en) * 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
CN106831553A (zh) * 2015-09-11 2017-06-13 天津科伦药物研究有限公司 贝曲西班或其类似物的制备方法
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
EP3254674A1 (en) * 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
WO2018093695A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440147B1 (en) * 1998-09-03 2002-08-27 Rubicor Medical, Inc. Excisional biopsy devices and methods
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
EP1156803A4 (en) * 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7312325B2 (en) 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
CN1780823A (zh) * 2003-04-09 2006-05-31 日本烟草产业株式会社 杂芳族五环化合物及其医药应用
JP4879745B2 (ja) * 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド 置換イソキノリノン
DE602004024910D1 (de) * 2003-10-09 2010-02-11 Millennium Pharm Inc Thioethersubstituierte benzamide als inhibitoren von faktor xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
KR101195801B1 (ko) * 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
JP2008528691A (ja) 2005-02-02 2008-07-31 ビテ ファーマシューティカルズ， インコーポレイテッド レニン阻害剤としての１−アシルアミノ−２−ヒドロキシ−３−アミノ−ω−アリールアルカン
US7467697B2 (en) * 2005-10-07 2008-12-23 Ford Global Technologies, Llc Electromagnetic coupling device for engine accessories
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
NZ592533A (en) 2005-11-08 2012-08-31 Millennium Pharm Inc METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
MX2008014193A (es) 2006-05-05 2009-03-31 Millennium Pharm Inc Inhibidores del factor xa.
CN105193799A (zh) * 2006-12-08 2015-12-30 米伦纽姆医药公司 使用经口因子xa抑制剂治疗血栓形成的单位剂量调配物和方法
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
EP2155195B1 (en) * 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor

Also Published As

Publication number Publication date
US20110033459A1 (en) 2011-02-10
ECSP099775A (es) 2010-01-29
ES2467468T3 (es) 2014-06-12
HK1138765A1 (en) 2010-09-03
IL201826A (en) 2014-08-31
KR101509829B1 (ko) 2015-04-06
KR20100023836A (ko) 2010-03-04
CA2684722A1 (en) 2008-11-13
JP2010526103A (ja) 2010-07-29
NZ599556A (en) 2013-10-25
EP2146705B1 (en) 2014-03-05
CN101686959A (zh) 2010-03-31
EP2146705A2 (en) 2010-01-27
WO2008137787A2 (en) 2008-11-13
IL201826A0 (en) 2010-06-16
EA200901442A1 (ru) 2010-06-30
TN2009000444A1 (en) 2011-03-31
EA020045B1 (ru) 2014-08-29
EP2586439A1 (en) 2013-05-01
AU2008247435A1 (en) 2008-11-13
CO6241105A2 (es) 2011-01-20
MX2009011755A (es) 2010-02-12
US20080279845A1 (en) 2008-11-13
PT2146705E (pt) 2014-05-23
NZ581324A (en) 2012-05-25
WO2008137787A3 (en) 2009-02-05
BRPI0811000A2 (pt) 2015-01-27
US8946219B2 (en) 2015-02-03
CN101686959B (zh) 2014-05-07
GT200900283A (es) 2011-10-05
JP5439363B2 (ja) 2014-03-12

Similar Documents

Publication Publication Date Title
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
EP2101757A4 (en) CONNECTION FOR TREATING OR PREVENTING DISORDERS OF THE PROSTATE AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEREOF OF A COLON DELIVERY SYSTEM
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
EP1605936A4 (en) ARYL-spiro hydantoin-CGRP Receptor Antagonists
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
EP1606264A4 (en) MONOCYCLIC ANILID SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EP1606286A4 (en) BENZODIAZEPINE SPIROHYDANTOINES AS CGRP RECEPTOR ANTAGONISTS
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
IL182317A0 (en) Cgrp receptor antagonists
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
NZ597648A (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
MY146947A (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites